Meteoreisen for Health & Longevity

Evidence Review created on 10/21/2026 using AI4L / Opus 5.5

Also known as: Meteoric Iron, Ferrum sidereum, Ferrum meteoricum, Meteoreisen Globuli velati, Meteoreisen comp., Meteoreisen Inject, Phosphorus, Phosphor, Quartz, Quarz, Bergkristall, Rock Crystal

Motivation

Meteoreisen (meteoric iron) is a remedy from anthroposophic medicine, a European healing tradition that began in the 1920s. Sold as small sugar globules, it combines iron from meteorites with phosphorus and quartz, each diluted to tiny amounts. Its maker presents it as a way to strengthen the body during colds, slow recovery after illness, and general exhaustion, which are complaints that matter to anyone who wants to stay energetic and resilient while aging.

The remedy grew out of a spiritual picture of meteoric iron as a force from the cosmos that works against weakness and fear. It has been sold in German pharmacies for decades, and doctors trained in anthroposophic medicine use it as a standard remedy for tiredness. Because its ingredients are diluted far below the amounts found in food, how it could act at all has long been debated.

This review examines what is known about Meteoreisen for health and longevity: the proposed ways it works, the human evidence for its claimed benefits, its possible harms, how it is used, and the quality and independence of the research behind it.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists accessible sources on the rationale behind Meteoreisen and on the evidence for the anthroposophic remedies to which it belongs.

• The Michael Imagination - Rudolf Steiner

  Steiner’s 1923 lecture describes meteoric iron as a cosmic healing force acting in the blood against fear; it is the primary source of the anthroposophic rationale behind Meteoreisen.

• Outcome of anthroposophic medication therapy in chronic disease: a 12-month prospective cohort study - Hamre et al., 2009

  Uncontrolled outcomes study of anthroposophic medications naming “Meteoric Iron Globuli for fatigue” as a standard regimen; funders included a health insurer, Weleda and WALA, Meteoreisen’s manufacturer.

• Anthroposophic medicine: a critical analysis - Ernst, 2008

  A critical review of anthroposophic medicine, the system that produces Meteoreisen, concluding that the effectiveness of its remedies is scientifically unproven (German text, English abstract).

• Kalium phosphoricum comp. in patients with neurasthenia: a randomized, double-blind, placebo-controlled clinical trial - Hellhammer et al., 2024

  Placebo-controlled trial of a related diluted-mineral anthroposophic remedy for nervous exhaustion, Meteoreisen’s target complaint; primary endpoints were null. Two co-authors work for the remedy’s manufacturer, Weleda.

Only four items qualified: writing on Meteoreisen itself is limited to product pages, glossary sites and a paywalled homeopathic journal article, which fall under the exclusions or could not be verified, so the list is not padded further.

No relevant content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; none of these sources covers Meteoreisen, meteoric-iron remedies or anthroposophic medications.

Grokipedia

Meteoric iron

Covers the source material, iron-nickel meteorites, their composition and ancient uses, but contains no information on Meteoreisen as a remedy, anthroposophic medicine or any health use.

Examine

No Examine article on Meteoreisen exists; searches for “Meteoreisen” and “meteoric iron” returned no results.

ConsumerLab

No ConsumerLab article on Meteoreisen exists; a search for “meteoric iron” returned only general iron-supplement content.

Systematic Reviews

No systematic reviews or meta-analyses for Meteoreisen were found on PubMed as of October 21, 2026.

Mechanism of Action

Meteoreisen combines three potentized (serially diluted and shaken) minerals (product leaflet): meteoric iron (Ferrum sidereum) at D11 (a decimal dilution of one part in 100 billion), phosphorus at D5 (one part in 100,000) and quartz at D11. Iron and quartz are potentized together over the final five steps.

• Anthroposophic rationale: The manufacturer states that meteoric iron strengthens the body and eases the drained feeling of infections, phosphorus counters lack of drive and nervous exhaustion, and quartz counters chilling (WALA). The three are combined for complementary, additive actions on one picture of exhaustion; no synergy has been measured.
• Pharmacological view: At these dilutions the product supplies iron and phosphorus many orders of magnitude below dietary intake, so no nutritional, blood-forming or toxic effect is expected. Half-life, selectivity, tissue distribution and metabolism have never been studied, and co-administration creates no known shared metabolic pathway or additive physiological effect.
• Competing explanations: Proponents point to laboratory evidence that metal-derived homeopathic dilutions retain nanoparticles of the starting metal (Chikramane et al., 2010), though no link to clinical effects has been shown. Critics attribute reported improvements to natural recovery, expectation and the care setting; open-label placebos (placebos given with full disclosure) reduced fatigue in a randomized trial (Hoenemeyer et al., 2018).

Historical Context & Evolution

• Original intended use: Anthroposophic medicine was founded by Rudolf Steiner and the physician Ita Wegman (Hamre et al., 2009). In a 1923 lecture Steiner described meteor showers “in high summer” as “cosmic iron” carrying “an enormously powerful healing force”, whose counterpart in human blood “wages war there on anxiety, fear and hate” (Steiner, 1923). This spiritual picture, not a laboratory finding, is the original rationale for medicinal meteoric iron.
• Product development: Rudolf Hauschka founded WALA in 1935 to produce anthroposophic medicines (Dr. Hauschka company history). Its Meteoreisen is labeled for flu-like infections, delayed convalescence (slow recovery after illness) and general exhaustion according to the anthroposophic understanding of man and nature (product leaflet).
• Route into health optimization: Anthroposophic physicians use it as a standardized fatigue regimen (Hamre et al., 2009), and interest in lingering post-infection tiredness keeps such remedies relevant to people seeking energy and resilience.
• Evolution of research: A 2004 systematic review found no randomized trials of the anthroposophic system as a whole (Ernst, 2004). Researchers then published large observational comparisons reporting faster recovery and fewer adverse reactions with anthroposophic care (Hamre et al., 2005), which drew a published critique (Ernst, 2005) and a reply (Hamre, 2005). Reviewers for Cochrane (an independent network producing systematic reviews) later found no consistent benefit of homeopathic products for childhood respiratory infections (Hawke et al., 2022). The question stays open because no study has isolated this remedy’s own effect.

Expected Benefits

No benefit of the three agents given together, or of meteoric iron, phosphorus or quartz alone in these dilutions, has been tested in a retrievable human study; a manufacturer-cited 2005 observational report in Der Merkurstab could not be retrieved or verified, so every item below rests on studies of other anthroposophic or homeopathic products.

High 🟩 🟩 🟩

No benefit reaches High: no controlled trial of Meteoreisen exists, and the human data are uncontrolled cohorts of anthroposophic care or trials of other remedies.

Medium 🟩 🟩

No benefit reaches Medium: there is no trial of Meteoreisen itself, and the comparative studies test whole anthroposophic treatment packages rather than this product.

Low 🟩

Relief of General Exhaustion and Delayed Convalescence ⚠️ Conflicted

An uncontrolled cohort reported symptom gains with anthroposophic medications overall (Hamre et al., 2009); evidence is indirect, as neither the combination nor any agent was analyzed separately. A placebo-controlled trial of a related exhaustion remedy failed its primary endpoints (Hellhammer et al., 2024). Net reading: no product-specific benefit is shown.

Magnitude: Disease Score (0–10) improved by 3.15 points (95% CI, confidence interval, the range likely to contain the true value: 2.97–3.34) after 6 months, no control group (Hamre et al., 2009); with the related remedy, the nervous-exhaustion symptom score (0–36) after 6 weeks was 10.6 versus 10.9 with placebo (p-value, a measure of how compatible the data are with no effect: 0.728), and no primary outcome differed from placebo (p-values 0.505–0.773) (Hellhammer et al., 2024).

Faster Recovery From Flu-Like Infections ⚠️ Conflicted

In a non-randomized comparison, anthroposophic care for respiratory infections showed faster recovery than conventional care (Hamre et al., 2005); evidence is indirect, testing neither this combination nor its agents. A Cochrane review in children found no consistent homeopathic benefit (Hawke et al., 2022). Net reading: benefit remains unproven.

Magnitude: Complete recovery by Day 7 in 30.5% of anthroposophic versus 23.3% of conventional patients, non-randomized (Hamre et al., 2005); pooled short-term cure with homeopathic products versus control OR (odds ratio, the relative odds of an outcome between groups) 1.31 (95% CI 0.09–19.54) (Hawke et al., 2022).

Speculative 🟨

Healthspan or Longevity Effects

No human or animal study has measured lifespan, healthspan or any aging marker with Meteoreisen. The basis is theoretical only: the anthroposophic idea that meteoric iron strengthens the body’s formative forces.

Improved Warmth Regulation

The manufacturer claims the remedy stimulates the body’s warmth production and that quartz counters chilling (WALA). No controlled study has measured body temperature or cold tolerance; the basis is anthroposophic theory only.

Benefit-Modifying Factors

• Genetic polymorphisms: No variant is known to modify a specific effect. In a placebo fatigue trial, carriers of the high-activity G version of the COMT (catechol-O-methyltransferase, an enzyme that breaks down dopamine) variant rs4680 improved more (Hoenemeyer et al., 2021), which may shape expectation-driven responses.
• Baseline biomarkers: Low ferritin (the body’s iron-storage protein), anemia or abnormal thyroid values point to a treatable cause. The remedy’s iron content cannot correct a deficiency, so any benefit can only be expected once such causes are excluded.
• Sex: No sex-specific data exist. Anthroposophic cohorts are predominantly women (Hamre et al., 2009), and iron-deficiency fatigue, which this product does not address, is more common in menstruating women.
• Pre-existing conditions: No data exist for chronic fatigue syndrome, depression or post-viral syndromes. The leaflet states that a clinically proven therapy is indicated for severe forms of the labeled conditions (Meteoreisen comp. leaflet).
• Age: No age-specific outcome data exist. In older adults, exhaustion more often has medical causes such as anemia, heart or thyroid disease, or medication effects, which lowers the share of cases a nonspecific remedy could plausibly address.

Potential Risks & Side Effects

No risk of the three agents given together, or of any single agent in these dilutions, has been measured in a study of Meteoreisen; no risk arising only from their co-administration is known, and the items below rest on leaflets and on studies of other products.

High 🟥 🟥 🟥

No risk reaches High: no trial of Meteoreisen has recorded adverse events, and the safety data come from cohorts of other anthroposophic or homeopathic products.

Medium 🟥 🟥

No risk reaches Medium: harms are documented only for the broader product classes or for substitution of effective care, not in controlled studies of this product.

Low 🟥

Delayed Diagnosis of a Treatable Cause of Fatigue

Exhaustion can signal anemia, thyroid disease, depression or cancer. Case reports document harm from substituting homeopathy for effective care (Posadzki et al., 2012), and alternative medicine alone for curable cancer was linked to higher mortality (Johnson et al., 2018). Evidence is indirect: other remedies, not this combination.

Magnitude: Risk of death HR (hazard ratio, the relative rate of an event over time) 2.50 (95% CI 1.88–3.27) with alternative medicine alone versus conventional cancer treatment, five-year survival 54.7% versus 78.3% (Johnson et al., 2018); 8 of 38 case reports concerned substitution harms, no control group (Posadzki et al., 2012).

Transient Symptom Aggravation or Hypersensitivity ⚠️ Conflicted

The combination’s Austrian leaflet lists allergy as a contraindication and warns of a transient “first reaction” (Meteoreisen comp. leaflet). A cohort of other anthroposophic medications found non-serious reactions (Hamre et al., 2006); homeopathy trials found no excess over control (Stub et al., 2016). Net reading: reactions are rare and non-serious.

Magnitude: Confirmed reactions in 3.0% (20 of 662) of anthroposophic-medication users, mostly aggravation of existing symptoms and none serious, no control group (Hamre et al., 2006); adverse-effect odds with homeopathic products versus control OR 0.99 (95% CI 0.86–1.14), group rates not reported in the abstract (Stub et al., 2016).

Speculative 🟨

Sugar Load in Sugar Intolerance

The globules are sucrose with lactose traces; leaflets ask people with sugar intolerance to consult a physician first (product leaflet). No harm is reported; the basis is this label warning only.

Contamination or Dilution Errors

The FDA (U.S. Food and Drug Administration) reports serious harm from homeopathic products containing measurable active ingredients or contaminants (FDA). No such report exists for Meteoreisen; the basis is isolated reports concerning other products.

New Symptoms With Prolonged Unsupervised Use

The combination’s Austrian leaflet warns that prolonged, non-indicated use can provoke new symptoms (called drug-proving symptoms) and calls for physician supervision (Meteoreisen comp. leaflet). No case is reported; the basis is this label warning only.

Risk-Modifying Factors

• Genetic polymorphisms: No variant affects tolerance of the active ingredients. Inherited sugar-handling disorders such as hereditary fructose intolerance (inability to break down fructose) raise concern about the sucrose carrier, which the leaflet addresses as sugar intolerance.
• Baseline biomarkers: Undiagnosed anemia, low ferritin or abnormal thyroid values raise the risk that the remedy postpones effective treatment, because Meteoreisen cannot correct any of them.
• Sex: No sex-based difference in adverse reactions is known. For pregnancy and breastfeeding no data exist, and the leaflet advises use only after consulting a physician or pharmacist (product leaflet).
• Pre-existing conditions: High fever, unexplained persistent fatigue, unintended weight loss or night sweats raise the stakes of delayed diagnosis. Known allergy to any ingredient is a contraindication in the Austrian leaflet.
• Age: Older adults carry a higher likelihood of serious underlying causes of exhaustion, so substitution risk rises with age; no age-related change in direct tolerability is described.

Key Interactions & Contraindications

• Drugs bound by oral iron (levothyroxine, ciprofloxacin, doxycycline, alendronate): No interaction expected (theoretical). Oral iron supplements reduce absorption of these drugs, but Meteoreisen’s iron content is negligible; severity: none, so no dose separation is needed beyond each drug’s own label.
• Iron-modifying therapies (deferasirox, intravenous ferric carboxymaltose): No interaction expected (theoretical); clinical consequence: none, because the remedy does not change iron status. Severity: monitor iron status as directed for the therapy itself, independent of Meteoreisen.
• Over-the-counter fever reducers (paracetamol, ibuprofen): No pharmacological interaction (theoretical). Caution: lowering fever can mask the 39 °C threshold at which the leaflet requires medical review (product leaflet); mitigation: peak temperatures are commonly recorded before dosing.
• Oral iron supplements (ferrous sulfate, ferrous bisglycinate): No interaction (theoretical); severity: none. Consequence to avoid: mistaking Meteoreisen for an iron source and skipping a needed supplement; the remedy adds no meaningful iron.
• Supplements with additive aims (vitamin D, zinc, other anthroposophic or homeopathic globules): No additive pharmacological effect (theoretical); severity: none. Combining several globule products only adds sugar; mitigation: physician coordination when several anthroposophic remedies are used.
• Stimulants and strong aromatic substances (coffee, alcohol, menthol, camphor): The Austrian leaflet states that stimulants and harmful lifestyle factors may weaken a homeopathic remedy’s effect (Meteoreisen comp. leaflet); severity: caution (theoretical), no human study; mitigation: doses are commonly kept apart from coffee.

Populations who should avoid Meteoreisen:

• People with known allergy to Ferrum sidereum, phosphorus, quartz or the excipients (contraindication, Meteoreisen comp. leaflet)
• Children under 1 year, for the Austrian product, because data are insufficient (Meteoreisen comp. leaflet)
• People with known sugar intolerance, unless a physician has been consulted (product leaflet)
• People with fever above 39 °C or with persistent or unclear complaints, as a sole treatment without medical review (product leaflet)
• Pregnant or breastfeeding women, unless a physician or pharmacist has been consulted (product leaflet)

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

• Medical evaluation before use for persistent exhaustion: A blood count, ferritin and thyroid test before attributing fatigue to a weak constitution prevents delayed diagnosis of anemia, iron deficiency or thyroid disease.
• Fever and time-limit stop rules: The Austrian leaflet requires medical review if fever exceeds 39 °C or lasts over 3 days, or after 7 days without improvement (Meteoreisen comp. leaflet); the German leaflet, 2 days (product leaflet). Prevents missed infection.
• Two-week limit for acute use: The leaflet ends acute treatment within 2 weeks, with longer use only after agreement with a physician (product leaflet). Limits prolonged reliance on an unproven remedy and resulting delayed care.
• Pause if symptoms worsen: Use stops if complaints intensify, resumes only after a first reaction subsides, and stops again if worsening recurs (Meteoreisen comp. leaflet). Mitigates transient aggravation reactions.
• Sugar intolerance check: With a known sugar intolerance, the leaflet requires consulting a physician before use (product leaflet); mitigates intolerance to the sucrose carrier.
• Licensed pharmacy sourcing: Buying the licensed WALA product through pharmacies rather than unregulated imports reduces the contamination and dilution-error risk the FDA describes for homeopathic products (FDA).

Therapeutic Protocol

Timing, splitting and other parameters without a citation reflect common practice.

• Standard dose (label): Adults and children from 12 years: 5–10 globules 1–3 times daily, dissolved sublingually (under the tongue) (product leaflet); the Austrian leaflet gives the same adult dose (Meteoreisen comp. leaflet).
• Practitioner regimen: Anthroposophic physicians use “Meteoric Iron Globuli” as a standardized fatigue regimen any physician can prescribe (Hamre et al., 2009); no published practitioner dose differs from the label. The approach was popularized by WALA and anthroposophic physicians.
• Alternative approaches: Anthroposophic physicians may instead individualize single Ferrum sidereum potencies from Weleda (product listing) or use Meteoreisen Inject ampoules (product listing); conventional practice treats identified causes and does not use the remedy.
• Combination regimen: The three ingredients come in one fixed ratio (0.1 g of each dilution per 10 g of globules) and are always taken together, at the same time (product leaflet).
• Time of day: No source specifies a time. Spreading doses across waking hours and keeping them apart from coffee is common practice, consistent with the Austrian leaflet’s note on stimulants.
• Half-life: Not applicable and never measured: the ingredient amounts are too small to track in blood, so no half-life guides dosing intervals.
• Single or split doses: The label allows one to three doses daily; split dosing during the acute phase and a single daily dose in recovery are common practice.
• Genetic polymorphisms: No variant is known to change dose. COMT variants influence placebo response in fatigue (Hoenemeyer et al., 2021) but carry no dosing implication.
• Sex: No sex-based difference in response or dose is described; the same label dose applies, with physician consultation in pregnancy and breastfeeding.
• Age: The adult dose applies from 12 years with no upper age limit; in older adults, ruling out medical causes of exhaustion before use is especially relevant.
• Baseline biomarkers: Normal blood count, ferritin and thyroid values are the setting in which the remedy is used; abnormal values redirect to targeted treatment rather than a dose change.
• Pre-existing conditions: For chronic illness, the duration of use requires agreement with a physician (product leaflet); severe forms call for a clinically proven therapy.

Discontinuation & Cycling

• Short-term by design: Acute use ends within 2 weeks; chronic use only with a physician (product leaflet). It is not intended as a lifelong intervention.
• Ingredients stopped together: As a fixed combination, the three ingredients cannot be stopped separately; stopping the globules stops all three.
• Withdrawal effects: None are reported, and the leaflets list no side effects; with ingredient amounts this small, dependence or rebound is not expected.
• Tapering: No source describes tapering, and none is needed; the remedy can be stopped at once.
• Cycling: No source describes cycling to maintain effect, and no tolerance mechanism is known.
• Stopping on recurrent worsening: If complaints intensify again after a first reaction, the Austrian leaflet calls for stopping (Meteoreisen comp. leaflet).

Sourcing and Quality

• Single manufacturer: Meteoreisen is made only by WALA Heilmittel GmbH in Bad Boll/Eckwälden, Germany, founded by Rudolf Hauschka in 1935 (Dr. Hauschka company history); it is pharmacy-only in Germany (product listing).
• Formulation: Globuli velati are sucrose globules coated with the potentized dilutions; WALA states they are free of alcohol and gluten (WALA). Austria sells the same composition as Meteoreisen comp. (Meteoreisen comp. leaflet).
• Each ingredient: Meteoric iron (Ferrum sidereum) derives from iron meteorites and is diluted to D11, phosphorus to D5, and quartz (rock crystal) to D11; iron and quartz are potentized jointly (product leaflet). No separate sourcing of the agents is possible.
• Related but different products: Weleda sells single Ferrum sidereum potencies and other combinations (product listing); these differ in composition and are not interchangeable with Meteoreisen.
• What to look for: A licensed medicinal product with an approval holder, batch number and expiry date, bought from a pharmacy. Third-party potency testing is not possible because the ingredient amounts lie below routine detection, so quality rests on regulated manufacturing.

Practical Considerations

• Time to effect: No study has measured it. Leaflets expect improvement in acute illness within 2 days (product leaflet) or 7 days (Meteoreisen comp. leaflet) and otherwise require medical review.
• Common pitfalls: Treating Meteoreisen as an iron supplement; using it for unexplained, months-long fatigue without blood tests; exceeding the two-week acute course; and confusing it with Weleda Ferrum sidereum products of different composition.
• Regulatory status in Europe: A licensed anthroposophic medicinal product, nonprescription and pharmacy-only in Germany (product listing); the Austrian leaflet states that its use rests exclusively on anthroposophic experience (Meteoreisen comp. leaflet).
• Regulatory status in the United States: No product labeled as homeopathic is FDA-approved, and such products have not been reviewed for safety and effectiveness (FDA).
• Cost and payers: The remedy is inexpensive and not difficult to access within Europe. A health insurer initiated the Anthroposophic Medicine Outcomes Study, the project behind the main supportive cohort (Hamre et al., 2009), a payer interest worth noting when weighing that research.

Interaction with Foundational Habits

• Sleep: No direct interaction is known; the leaflets report no sleep effects. Indirect: short or poor sleep is a leading cause of daytime exhaustion, so restoring sleep is the first-line factor for the complaint this remedy targets; persistent unrefreshing sleep warrants evaluation for sleep apnea (repeated breathing pauses during sleep).
• Nutrition: No direct interaction; the remedy provides no meaningful iron or phosphorus. Iron status depends on diet (red meat, legumes, leafy greens with vitamin C) and absorption. The Austrian leaflet says stimulants may weaken homeopathic effects (Meteoreisen comp. leaflet), so many users separate doses from coffee.
• Exercise: No direct or blunting interaction is known. Indirect: after an infection, a graded return to training supports recovery, and exhaustion that worsens after exertion or persists for weeks is a signal for medical review rather than more remedy use.
• Stress management: Indirect interaction through expectation and care context, which can ease fatigue even with openly labeled placebos (Hoenemeyer et al., 2018). A related remedy for stress-linked nervous exhaustion did not beat placebo (Hellhammer et al., 2024); proven stress-reduction practices remain independent levers.

Monitoring Protocol & Defining Success

Before starting Meteoreisen for exhaustion or slow recovery lasting more than a few weeks, baseline testing establishes whether a treatable cause exists: a blood count, ferritin and thyroid function, plus a validated fatigue questionnaire to record a starting score. For a short course during a flu-like infection, no laboratory baseline is needed; temperature and symptom severity are recorded instead.

Ongoing monitoring follows this cadence: temperature daily during acute illness, a symptom review at 2 days and 7 days (the leaflet thresholds), a fatigue score at 2 weeks when the acute course ends, and repeat blood tests at 3 months only if exhaustion persists or the blood tests were abnormal. Success means a clear, sustained improvement in fatigue score and daily function, while failure to improve by the leaflet deadlines signals the need for medical evaluation.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Hemoglobin	Women about 12.0–15.5 g/dL; men about 13.5–17.5 g/dL (standard reference range)	Safety check: anemia redirects to targeted treatment	Ranges vary by laboratory; no fasting needed; pair with ferritin; Meteoreisen supplies no meaningful iron
Ferritin	Women about 15–150 ng/mL; men about 30–400 ng/mL (standard reference range)	Safety check: low stores change use	Ferritin rises with inflammation, so pair with CRP (C-reactive protein, a marker of inflammation); avoid testing during acute infection
TSH	About 0.4–4.0 mIU/L (standard reference range)	Safety check: thyroid disease changes use	TSH (thyroid-stimulating hormone, the main screening marker of thyroid function); morning draw preferred; pause biotin supplements 2–3 days before testing
Fatigue Severity Scale score	No established target; track change from the individual’s own baseline	Expected to change: measures the claimed effect	Validated 9-item questionnaire; score at baseline and at 2 weeks under similar conditions (time of day, sleep, training load)

Qualitative markers:

• Energy on waking and in the afternoon
• Days until return to usual activity after an infection
• Exercise tolerance and recovery after training
• Sleep quality and daytime alertness
• Mood and motivation (drive)

Emerging Research

• No registered trial of Meteoreisen: ClinicalTrials.gov lists no study of Meteoreisen, meteoric iron or Ferrum sidereum. Until one exists, its specific effect on exhaustion remains untested, and claims rest on tradition, manufacturer statements and studies of other anthroposophic products.
• Homeopathy for long COVID (pilot trial): Randomized pilot of homeopathic remedies versus usual care in 120 adults (NCT07694232), not yet recruiting, completion 2028; primary outcome MYMOP (Measure Yourself Medical Outcome Profile, a patient-chosen symptom score). A positive result would modestly support diluted remedies for post-infection fatigue; a null result would weaken that case.
• Planned systematic review series: A 2026 protocol outlines systematic reviews of homeopathic preparations used in anthroposophic medicine and homeopathy (Loef et al., 2026). Reviews covering exhaustion or respiratory infections could either support or further undercut the indirect evidence for Meteoreisen.
• Physical traces in diluted metals: Nanoparticles of starting metals were reported in market homeopathic dilutions (Chikramane et al., 2010). Independent replication and dose-response data for iron preparations could strengthen biological plausibility; failure to replicate would weaken it.
• Placebo-response research in fatigue: Openly labeled placebos reduced fatigue in a randomized trial (Hoenemeyer et al., 2018), with response linked to COMT genotype (Hoenemeyer et al., 2021). Further work may explain reported benefits of remedies like Meteoreisen as context effects, weakening claims of a specific action.

Conclusion

Meteoreisen is a fixed anthroposophic remedy that combines meteoric iron, phosphorus and quartz in extreme dilutions and is sold for flu-like infections, slow recovery after illness and general exhaustion. Its rationale rests on a spiritual picture of meteoric iron as a force against weakness and fear rather than on measured effects of its ingredients, which are present far below food-level or harmful amounts.

No retrievable study has tested Meteoreisen itself; a manufacturer-cited report on users could not be checked. The supportive human data come from studies of anthroposophic care as a whole that lacked fair comparison groups, in which people reported feeling better. A placebo comparison of a related exhaustion remedy and an independent review of similar diluted remedies for respiratory infections found no consistent benefit. The main supportive project was funded partly by a health insurer and by remedy makers, including the maker of Meteoreisen, which is also the main source of its claimed effects; employees of a remedy maker co-wrote the placebo comparison. Nothing links the remedy to longer life or slower aging.

Direct harms appear rare and not serious, in line with the tiny ingredient amounts and the sugar carrier. The more relevant risk for a proactive, health-focused person is indirect: treating lasting exhaustion with an unproven remedy can postpone finding a correctable cause such as iron deficiency, thyroid disease or depression. Within those limits, Meteoreisen is a low-cost, low-risk product whose benefits beyond expectation and natural recovery have not been demonstrated.

Top - Benefits - Risks - Protocol